Article Figures & Data
Figures
- Figure 1 Distribution of DMD Mutations in Patients With DMD in Countries
Overview of mutation distribution in patients with DMD from Eastern Europe (A) and Algeria (B). Nonsense mutations were the most frequently occurring mutations in Eastern European patients, accounting for 31% of mutation types in the patients with DMD, followed by deletions (29%), frameshifting (18%), duplications (11%), and splicing canonical sites (9%); missense and consensus splicing are the least frequent (1% each). Deletions were the most frequent mutations in Algerian patients (77%), whereas nonsense (5%), frameshifting (5%), splicing canonical sites (5%), duplication (5%), and missense (3%) variations were the least frequent. No splicing consensus sequence mutations were identified in patients from Algeria. The reported numbers include known and novel, likely pathogenic, mutations/variations, but not VUS. Among the 28 females tested for carrier detection, we found 11 carriers, all heterozygous for large deletions (6) and small mutations (5). The remaining females were not carriers. The 2 patients from Cyprus were not included in the statistical analysis as 1 patient showed an exon 2 duplication, whereas the other resulted negative. DMD = Duchenne muscular dystrophy; VUS = variant of uncertain/unknown significance.
- Figure 2 Country Distribution of DMD Mutations in Patients With DMD in Eastern European Countries
Geographical distribution of DMD mutations in Eastern European countries and relative number of patients (in brackets). The percentages for each type of DMD mutation are shown for each country. In countries with more than 30 patients with DMD carrying a DMD mutation, differences can be noted because Polish and Ukrainian patients have a similar mutation landscape with a very high frequency of small mutations (average of 55%), whereas in Romania, 31% of mutation types are small mutations with deletions, and 69% account for duplications. DMD = Duchenne muscular dystrophy.
- Figure 3 Integrative Genome Viewer (IGV) Visualization
(A) IGV visualization of sample 2533/18. Visualization of sample 2533/18 with deletion of exon 51: (a) there is no coverage or readings of exon 51. (b and c) Visualization of coverage and reads of exons 50 and 52, which precede and follow the deletion of exon 51, respectively. (B) IGV visualization of sample 2526/18. Visualization of sample 2526/18 with deletion of exons 18–19. (a) This figure shows that there is no coverage or readings corresponding to exons 18 and 19. (b and c) Visualization of coverage and reads of the flanking exon 17 preceding the deletion and of exon 20 following the deletion.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Topics Discussed
Alert Me
Recommended articles
WGS and RNA Studies Diagnose Noncoding DMD Variants in Males With High Creatine Kinase
Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy
DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy